Skip to main content
icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Технологии·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Технологии·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

38% вероятность
Polymarket
НОВОЕ
38% вероятность
Polymarket
НОВОЕ
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s strategic pivot toward oral GLP-1 agonists and competing long-acting delivery platforms underpins the 61.5% implied probability that no commercial license for Peptron’s SmartDepot sustained-release microsphere technology will be signed by October 7. The October 2024 technology evaluation agreement, extended into 2026, remains limited to non-exclusive internal research on peptide candidates without binding commercial terms, while Lilly’s June 2025 Camurus FluidCrystal deal and April 2026 Foundayo oral approval signal a broader preference for differentiated formulations and manufacturing scale-up in Indiana. Trader sentiment reflects the absence of recent progress updates from Lilly’s South Korea hub or earnings commentary, leaving the window for a formal technology transfer or licensing deal narrow amid competing priorities.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Объем
$8,224
Дата окончания
7 окт. 2026 г.
Открытие рынка
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s strategic pivot toward oral GLP-1 agonists and competing long-acting delivery platforms underpins the 61.5% implied probability that no commercial license for Peptron’s SmartDepot sustained-release microsphere technology will be signed by October 7. The October 2024 technology evaluation agreement, extended into 2026, remains limited to non-exclusive internal research on peptide candidates without binding commercial terms, while Lilly’s June 2025 Camurus FluidCrystal deal and April 2026 Foundayo oral approval signal a broader preference for differentiated formulations and manufacturing scale-up in Indiana. Trader sentiment reflects the absence of recent progress updates from Lilly’s South Korea hub or earnings commentary, leaving the window for a formal technology transfer or licensing deal narrow amid competing priorities.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Объем
$8,224
Дата окончания
7 окт. 2026 г.
Открытие рынка
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.

Не доверяй внешним ссылкам.

Часто задаваемые вопросы

«Eli Lilly licenses Peptron’s SmartDepot by October 7?» — это рынок прогнозов на Polymarket, где трейдеры покупают и продают акции «Да» или «Нет» в зависимости от того, верят ли они, что это событие произойдёт. Текущая вероятность по мнению сообщества составляет 38% для «Yes». Например, если «Да» торгуется по 38¢, рынок коллективно оценивает вероятность наступления события в 38%. Эти коэффициенты постоянно меняются по мере реакции трейдеров на новые события и информацию. Акции правильного исхода можно обменять на $1 каждую при разрешении рынка.

«Eli Lilly licenses Peptron’s SmartDepot by October 7?» — недавно созданный рынок на Polymarket, запущен May 6, 2026. Как ранний рынок, это твоя возможность быть среди первых трейдеров, устанавливающих коэффициенты и формирующих начальные ценовые сигналы. Ты также можешь добавить эту страницу в закладки, чтобы следить за объёмом и активностью торгов.

Чтобы торговать на «Eli Lilly licenses Peptron’s SmartDepot by October 7?», просто выбери, считаешь ли ты, что ответ — «Да» или «Нет». Каждая сторона имеет текущую цену, отражающую подразумеваемую вероятность рынка. Введи сумму и нажми «Торговать». Если ты купишь акции «Да» и исход разрешится как «Да», каждая акция принесёт $1. Если исход — «Нет», твои акции «Да» принесут $0. Ты также можешь продать свои акции в любой момент до разрешения, чтобы зафиксировать прибыль или ограничить убыток.

Текущая вероятность для «Eli Lilly licenses Peptron’s SmartDepot by October 7?» составляет 38% для «Yes». Это означает, что сообщество Polymarket в настоящее время оценивает вероятность наступления этого события в 38%. Эти коэффициенты обновляются в реальном времени на основе реальных сделок, предоставляя постоянно обновляемый сигнал ожиданий рынка.

Правила разрешения «Eli Lilly licenses Peptron’s SmartDepot by October 7?» точно определяют, что должно произойти, чтобы каждый исход был объявлен победителем, включая официальные источники данных, используемые для определения результата. Ты можешь просмотреть полные критерии разрешения в разделе «Правила» на этой странице над комментариями. Мы рекомендуем внимательно прочитать правила перед торговлей, так как они определяют точные условия, особые случаи и источники.